


Figure 1

DL: dose level; DLT: dose-limiting toxicity; RP2D: recommended phase 2 dose

Note: In case of 2 or more DLTs at DL-1, the study part may be stopped or the dosage reconsidered.

Figure 2





Figure 3



CEACAM5: carcinoembryonic antigen-related cell adhesion molecule 5; EOT: end of treatment; ICF: informed consent form; NSQ NSCLC: non-squamous, non-small-cell lung cancer

Figure 4




Figure 5




Figure 6

